Quarterly report [Sections 13 or 15(d)]

Share-Based Compensation - Summary of Activity Under Share-Based Compensation Plans (Detail)

v3.25.2
Share-Based Compensation - Summary of Activity Under Share-Based Compensation Plans (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Outstanding and nonvested as of December 31, 2024, Number of Shares [1]     6,289    
Granted, Number of Shares [2]     1,779    
Vested, Number of Shares     (2,725)    
Forfeited, Number of Shares     (388)    
Outstanding and nonvested as of June 30, 2025, Number of Shares [1] 4,955   4,955   6,289
Expected to vest as of June 30, 2025, Number of Shares [3] 4,533   4,533    
Outstanding and nonvested as of December 31, 2024, Weighted Average Grant Date Fair Value Per Share [1]     $ 12.56    
Granted, Weighted Average Grant Date Fair Value Per Share [2]     8.1    
Vested, Weighted Average Grant Date Fair Value Per Share     15.14    
Forfeited, Weighted Average Grant Date Fair Value Per Share     10.85    
Outstanding and nonvested as of June 30, 2025, Weighted Average Grant Date Fair Value Per Share [1] $ 9.68   9.68   $ 12.56
Expected to vest as of June 30, 2025, Weighted Average Grant Date Fair Value Per Share [3] $ 9.77   $ 9.77    
Stock Appreciation Rights (SARs)          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of Awards Outstanding, Beginning Balance [4]     11,002    
Granted, Number of Awards [5]     2,646    
Exercised, Number of Awards     0    
Forfeited, Number of Awards [6]     (467)    
Number of Awards Outstanding, Ending Balance [4] 13,181   13,181   11,002
Number of Awards Exercisable, Ending Balance [7] 4,269   4,269    
Number of Awards Vested and expected to vest, Ending Balance [8] 9,466   9,466    
Weighted Average Exercise Price Per Award Outstanding, Beginning Balance [4]     $ 12.12    
Granted, Weighted Average Exercise Price Per Award [5]     7.72    
Exercised, Weighted Average Exercise Price Per Award     0    
Forfeited, Weighted Average Exercise Price Per Award [6]     16.27    
Weighted Average Exercise Price Per Award Outstanding, Ending Balance [4] $ 11.09   11.09   $ 12.12
Exercisable, Weighted Average Exercise Price Per Award, Ending Balance [7] 15.77   15.77    
Weighted Average Exercise Price Per Award, Vested and expected to vest, Ending Balance [8] $ 12.2   $ 12.2    
Weighted Average Remaining Contractual Term Outstanding [4]     7 years 6 months   7 years 1 month 6 days
Exercisable Weighted Average Remaining Contractual Term [4]     6 years 9 months 18 days    
Weighted Average Remaining Contractual Term, Vested and expected to vest [4]     8 years 1 month 6 days    
Aggregate Intrinsic Value Outstanding [4],[9] $ 4.9   $ 4.9   $ 0.0
Exercisable, Aggregate Intrinsic Value [7],[9] 0.3   0.3    
Aggregate Intrinsic Value, Vested and expected to vest [8],[9] $ 2.9   $ 2.9    
Granted, Weighted Average Grant Date Fair Value Per Share $ 3.88 $ 4.94 $ 4.14 $ 4.51  
[1] Includes 1.6 million performance-based restricted stock units as of June 30, 2025, which represents the maximum amount that can vest. There were no performance-based restricted stock units outstanding as of December 31, 2024.
[2] Includes 1.6 million performance-based restricted stock units.
[3] Includes 1.2 million performance-based restricted stock units.
[4] Includes 3.9 million and 4.0 million performance condition SARs as of June 30, 2025 and December 31, 2024, respectively.
[5] Includes 0.1 million performance condition SARs.
[6] Includes 0.1 million performance condition SARs.
[7] Includes 0.4 million performance condition SARs.
[8] Includes 0.5 million performance condition SARs.
[9] The intrinsic value is the amount by which the current market value of the underlying stock exceeds the exercise price of the stock awards.